 T. Reece
Concepts (578)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Ischemia | 23 | 2022 | 63 | 10.540 |
Why?
| | Aorta, Thoracic | 36 | 2022 | 246 | 8.130 |
Why?
| | Reperfusion Injury | 22 | 2021 | 254 | 6.800 |
Why?
| | Spinal Cord | 20 | 2022 | 351 | 5.660 |
Why?
| | Blood Vessel Prosthesis Implantation | 16 | 2023 | 180 | 5.020 |
Why?
| | Aortic Aneurysm, Thoracic | 18 | 2023 | 117 | 4.970 |
Why?
| | Cardiac Surgical Procedures | 30 | 2022 | 413 | 4.350 |
Why?
| | Aortic Valve | 27 | 2021 | 342 | 3.870 |
Why?
| | Erythropoietin | 7 | 2018 | 72 | 3.790 |
Why?
| | Aortic Aneurysm | 10 | 2022 | 50 | 3.530 |
Why?
| | Paraplegia | 14 | 2023 | 52 | 3.500 |
Why?
| | Spinal Cord Injuries | 10 | 2022 | 173 | 3.330 |
Why?
| | Heart Valve Diseases | 10 | 2020 | 116 | 2.950 |
Why?
| | Diazoxide | 5 | 2021 | 22 | 2.820 |
Why?
| | Vascular Surgical Procedures | 10 | 2020 | 262 | 2.730 |
Why?
| | Thoracic Surgery | 12 | 2022 | 105 | 2.670 |
Why?
| | Cerebrovascular Circulation | 7 | 2022 | 202 | 2.500 |
Why?
| | Aortic Diseases | 8 | 2021 | 95 | 2.360 |
Why?
| | Receptors, Erythropoietin | 4 | 2018 | 21 | 2.330 |
Why?
| | Heart Valve Prosthesis Implantation | 11 | 2020 | 169 | 2.190 |
Why?
| | Neuroprotective Agents | 5 | 2018 | 105 | 2.010 |
Why?
| | Aorta | 11 | 2021 | 353 | 1.960 |
Why?
| | Dexmedetomidine | 5 | 2014 | 45 | 1.860 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 4 | 2014 | 24 | 1.780 |
Why?
| | Hypothermia, Induced | 5 | 2022 | 69 | 1.780 |
Why?
| | Surgeons | 5 | 2022 | 238 | 1.760 |
Why?
| | Cyclohexanecarboxylic Acids | 8 | 2008 | 22 | 1.710 |
Why?
| | Purines | 8 | 2008 | 159 | 1.600 |
Why?
| | Subclavian Artery | 5 | 2020 | 29 | 1.540 |
Why?
| | Postoperative Complications | 24 | 2022 | 2161 | 1.500 |
Why?
| | Cardiology | 5 | 2019 | 260 | 1.420 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 6 | 2022 | 20 | 1.410 |
Why?
| | Thoracic Surgical Procedures | 5 | 2022 | 57 | 1.400 |
Why?
| | Aortic Valve Stenosis | 13 | 2021 | 253 | 1.320 |
Why?
| | Neuroprotection | 3 | 2017 | 30 | 1.300 |
Why?
| | Heart Arrest, Induced | 4 | 2021 | 30 | 1.290 |
Why?
| | Aortic Valve Insufficiency | 5 | 2018 | 44 | 1.260 |
Why?
| | Microglia | 4 | 2013 | 203 | 1.250 |
Why?
| | Toll-Like Receptor 4 | 11 | 2020 | 285 | 1.250 |
Why?
| | Humans | 149 | 2023 | 115587 | 1.230 |
Why?
| | Endovascular Procedures | 7 | 2023 | 269 | 1.220 |
Why?
| | Mitral Valve | 6 | 2020 | 84 | 1.190 |
Why?
| | Mice, Inbred C57BL | 19 | 2021 | 4773 | 1.120 |
Why?
| | Dissection | 4 | 2020 | 52 | 1.060 |
Why?
| | Cardiopulmonary Bypass | 9 | 2022 | 176 | 1.020 |
Why?
| | Heart Transplantation | 9 | 2023 | 671 | 0.990 |
Why?
| | Ischemia | 5 | 2021 | 363 | 0.980 |
Why?
| | Adenosine A2 Receptor Agonists | 6 | 2007 | 19 | 0.980 |
Why?
| | Disease Models, Animal | 17 | 2021 | 3580 | 0.970 |
Why?
| | Heart Diseases | 5 | 2019 | 330 | 0.950 |
Why?
| | Intraoperative Neurophysiological Monitoring | 2 | 2021 | 15 | 0.950 |
Why?
| | Up-Regulation | 6 | 2020 | 820 | 0.950 |
Why?
| | Lung Transplantation | 7 | 2019 | 246 | 0.940 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 15 | 0.890 |
Why?
| | Receptor, Adenosine A2A | 6 | 2008 | 20 | 0.880 |
Why?
| | Mice | 24 | 2021 | 15052 | 0.840 |
Why?
| | Male | 80 | 2023 | 55949 | 0.830 |
Why?
| | Animals | 41 | 2021 | 32102 | 0.810 |
Why?
| | Periodicals as Topic | 2 | 2015 | 183 | 0.800 |
Why?
| | Troponin I | 1 | 2022 | 68 | 0.800 |
Why?
| | STAT3 Transcription Factor | 3 | 2018 | 174 | 0.790 |
Why?
| | Treatment Outcome | 26 | 2023 | 9159 | 0.770 |
Why?
| | Anesthesiology | 3 | 2018 | 36 | 0.770 |
Why?
| | Perfusion | 5 | 2022 | 150 | 0.760 |
Why?
| | Signal Transduction | 14 | 2020 | 4541 | 0.730 |
Why?
| | Cardiovascular Abnormalities | 1 | 2020 | 11 | 0.710 |
Why?
| | Beauty | 1 | 2020 | 11 | 0.710 |
Why?
| | Aortic Rupture | 2 | 2018 | 25 | 0.710 |
Why?
| | Carotid Artery, Common | 1 | 2020 | 30 | 0.700 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2020 | 40 | 0.700 |
Why?
| | Calcinosis | 6 | 2018 | 242 | 0.690 |
Why?
| | Nervous System Diseases | 2 | 2021 | 253 | 0.690 |
Why?
| | Hospital Mortality | 14 | 2022 | 779 | 0.690 |
Why?
| | Societies, Medical | 9 | 2022 | 684 | 0.670 |
Why?
| | Politics | 1 | 2020 | 79 | 0.670 |
Why?
| | Acidosis | 1 | 2020 | 87 | 0.670 |
Why?
| | Blood Vessel Prosthesis | 6 | 2023 | 113 | 0.660 |
Why?
| | Spinal Cord Stimulation | 1 | 2019 | 7 | 0.660 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 549 | 0.660 |
Why?
| | Lower Extremity | 2 | 2014 | 337 | 0.660 |
Why?
| | Osteogenesis | 7 | 2019 | 184 | 0.660 |
Why?
| | Heart Arrest | 1 | 2022 | 289 | 0.650 |
Why?
| | Blood Transfusion | 3 | 2020 | 277 | 0.650 |
Why?
| | Nerve Growth Factor | 1 | 2018 | 27 | 0.630 |
Why?
| | Retrospective Studies | 35 | 2023 | 12608 | 0.620 |
Why?
| | CREB-Binding Protein | 2 | 2014 | 27 | 0.600 |
Why?
| | Middle Aged | 49 | 2023 | 26999 | 0.600 |
Why?
| | Anesthesia | 2 | 2016 | 119 | 0.590 |
Why?
| | Population Surveillance | 1 | 2020 | 395 | 0.590 |
Why?
| | Catheterization | 1 | 2018 | 159 | 0.590 |
Why?
| | Prosthesis Design | 1 | 2019 | 287 | 0.580 |
Why?
| | Neurons | 5 | 2020 | 1298 | 0.580 |
Why?
| | Nicorandil | 3 | 2021 | 10 | 0.580 |
Why?
| | Catheterization, Peripheral | 2 | 2016 | 102 | 0.570 |
Why?
| | Stents | 6 | 2023 | 475 | 0.570 |
Why?
| | Thoracotomy | 3 | 2014 | 67 | 0.550 |
Why?
| | Coronary Artery Bypass | 7 | 2016 | 196 | 0.530 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2015 | 4 | 0.530 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 35 | 0.520 |
Why?
| | Femoral Artery | 3 | 2015 | 167 | 0.510 |
Why?
| | Time Factors | 17 | 2023 | 6165 | 0.510 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 495 | 0.510 |
Why?
| | Aged | 35 | 2023 | 19251 | 0.510 |
Why?
| | Clinical Protocols | 1 | 2016 | 234 | 0.500 |
Why?
| | Mitochondria | 1 | 2020 | 750 | 0.500 |
Why?
| | Chemokines | 2 | 2015 | 214 | 0.500 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.490 |
Why?
| | Tissue and Organ Procurement | 5 | 2023 | 243 | 0.480 |
Why?
| | Cell Survival | 7 | 2017 | 1024 | 0.480 |
Why?
| | Risk Factors | 15 | 2022 | 8697 | 0.470 |
Why?
| | Apoptosis | 4 | 2018 | 2377 | 0.470 |
Why?
| | Motor Activity | 3 | 2014 | 633 | 0.460 |
Why?
| | Heart Valve Prosthesis | 4 | 2018 | 118 | 0.460 |
Why?
| | Cells, Cultured | 13 | 2021 | 3914 | 0.460 |
Why?
| | Survival Rate | 12 | 2019 | 1650 | 0.450 |
Why?
| | Multimodal Imaging | 3 | 2019 | 98 | 0.450 |
Why?
| | Esophagus | 1 | 2015 | 226 | 0.450 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 373 | 0.440 |
Why?
| | Risk Assessment | 13 | 2020 | 2987 | 0.440 |
Why?
| | Intermittent Claudication | 1 | 2014 | 108 | 0.430 |
Why?
| | Astrocytes | 1 | 2014 | 163 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2392 | 0.420 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2020 | 352 | 0.420 |
Why?
| | Models, Cardiovascular | 2 | 2017 | 172 | 0.420 |
Why?
| | American Heart Association | 3 | 2019 | 266 | 0.420 |
Why?
| | Pulmonary Valve | 1 | 2013 | 90 | 0.400 |
Why?
| | Acute Disease | 6 | 2021 | 914 | 0.400 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2019 | 482 | 0.400 |
Why?
| | Prognosis | 9 | 2022 | 3339 | 0.400 |
Why?
| | Acute Kidney Injury | 5 | 2022 | 646 | 0.400 |
Why?
| | Adult | 32 | 2023 | 30718 | 0.390 |
Why?
| | Cause of Death | 1 | 2013 | 368 | 0.390 |
Why?
| | Anesthetics | 1 | 2011 | 57 | 0.390 |
Why?
| | Vascular Diseases | 2 | 2016 | 230 | 0.390 |
Why?
| | United States | 21 | 2023 | 12295 | 0.390 |
Why?
| | Myelitis | 1 | 2012 | 88 | 0.380 |
Why?
| | Aorta, Abdominal | 1 | 2011 | 38 | 0.380 |
Why?
| | Female | 50 | 2023 | 59913 | 0.370 |
Why?
| | Axillary Artery | 3 | 2018 | 12 | 0.370 |
Why?
| | Anti-Inflammatory Agents | 4 | 2013 | 448 | 0.370 |
Why?
| | Monitoring, Intraoperative | 3 | 2021 | 39 | 0.360 |
Why?
| | Mitral Valve Insufficiency | 5 | 2015 | 63 | 0.350 |
Why?
| | Replantation | 3 | 2019 | 32 | 0.350 |
Why?
| | Heart-Assist Devices | 5 | 2019 | 486 | 0.350 |
Why?
| | Aortic Arch Syndromes | 1 | 2009 | 2 | 0.350 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 1098 | 0.350 |
Why?
| | Simvastatin | 3 | 2019 | 59 | 0.340 |
Why?
| | Diverticulum | 1 | 2009 | 11 | 0.340 |
Why?
| | Cardiovascular Diseases | 3 | 2019 | 1724 | 0.340 |
Why?
| | Pneumonectomy | 2 | 2008 | 126 | 0.340 |
Why?
| | Brachiocephalic Trunk | 3 | 2018 | 11 | 0.330 |
Why?
| | Anastomosis, Surgical | 3 | 2019 | 140 | 0.330 |
Why?
| | Angiography | 3 | 2019 | 177 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2014 | 400 | 0.330 |
Why?
| | Heart | 5 | 2023 | 608 | 0.330 |
Why?
| | Lung | 7 | 2011 | 3672 | 0.320 |
Why?
| | Regional Blood Flow | 4 | 2019 | 414 | 0.320 |
Why?
| | Phospholipases A2, Secretory | 3 | 2014 | 23 | 0.320 |
Why?
| | Adenocarcinoma | 5 | 2018 | 799 | 0.320 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2021 | 243 | 0.320 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1447 | 0.320 |
Why?
| | Echocardiography | 5 | 2019 | 558 | 0.310 |
Why?
| | Phosphorylation | 4 | 2018 | 1571 | 0.310 |
Why?
| | Peripheral Arterial Disease | 1 | 2014 | 379 | 0.310 |
Why?
| | Esophageal Neoplasms | 4 | 2018 | 273 | 0.310 |
Why?
| | Deglutition Disorders | 1 | 2009 | 119 | 0.300 |
Why?
| | Thrombocytopenia | 2 | 2020 | 175 | 0.300 |
Why?
| | Hemodynamics | 4 | 2018 | 968 | 0.300 |
Why?
| | Coronary Artery Disease | 3 | 2020 | 607 | 0.300 |
Why?
| | Heart Failure | 7 | 2019 | 1963 | 0.300 |
Why?
| | Adenosine A2 Receptor Antagonists | 2 | 2006 | 10 | 0.300 |
Why?
| | Myofibroblasts | 3 | 2018 | 116 | 0.300 |
Why?
| | Collateral Circulation | 2 | 2019 | 19 | 0.300 |
Why?
| | Rabbits | 8 | 2008 | 752 | 0.300 |
Why?
| | Myocardial Ischemia | 4 | 2018 | 237 | 0.290 |
Why?
| | Operative Time | 2 | 2019 | 109 | 0.270 |
Why?
| | Intraoperative Care | 2 | 2022 | 36 | 0.270 |
Why?
| | Follow-Up Studies | 10 | 2019 | 4440 | 0.270 |
Why?
| | Hindlimb | 4 | 2012 | 125 | 0.270 |
Why?
| | Stroke | 4 | 2023 | 1016 | 0.270 |
Why?
| | Cell Culture Techniques | 3 | 2019 | 344 | 0.260 |
Why?
| | Suture Techniques | 5 | 2020 | 130 | 0.260 |
Why?
| | Organ Preservation Solutions | 2 | 2023 | 42 | 0.260 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 81 | 0.260 |
Why?
| | Syndrome | 3 | 2021 | 339 | 0.250 |
Why?
| | Myocardium | 4 | 2020 | 926 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2013 | 1137 | 0.250 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 795 | 0.250 |
Why?
| | Recombinant Proteins | 4 | 2018 | 1243 | 0.240 |
Why?
| | Coronary Vessel Anomalies | 2 | 2016 | 30 | 0.240 |
Why?
| | Tissue Adhesives | 2 | 2018 | 17 | 0.230 |
Why?
| | Toll-Like Receptor 2 | 3 | 2020 | 112 | 0.230 |
Why?
| | Coronary Vessels | 2 | 2018 | 229 | 0.230 |
Why?
| | Length of Stay | 6 | 2020 | 958 | 0.230 |
Why?
| | Constriction | 3 | 2013 | 45 | 0.230 |
Why?
| | Endoleak | 2 | 2023 | 13 | 0.230 |
Why?
| | NF-kappa B | 6 | 2020 | 639 | 0.220 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 32 | 0.220 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2014 | 106 | 0.220 |
Why?
| | Aortography | 3 | 2019 | 48 | 0.220 |
Why?
| | Consensus | 3 | 2020 | 532 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 214 | 0.210 |
Why?
| | Time-to-Treatment | 2 | 2022 | 147 | 0.210 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2018 | 166 | 0.210 |
Why?
| | Analysis of Variance | 3 | 2019 | 1227 | 0.210 |
Why?
| | Educational Personnel | 1 | 2022 | 13 | 0.210 |
Why?
| | Blotting, Western | 4 | 2018 | 1153 | 0.210 |
Why?
| | Fibrosis | 3 | 2020 | 457 | 0.210 |
Why?
| | Cohort Studies | 6 | 2020 | 4944 | 0.200 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 225 | 0.200 |
Why?
| | Pleural Effusion | 1 | 2022 | 46 | 0.200 |
Why?
| | Echocardiography, Transesophageal | 2 | 2013 | 89 | 0.200 |
Why?
| | Reoperation | 4 | 2014 | 525 | 0.200 |
Why?
| | Renal Insufficiency | 1 | 2023 | 137 | 0.200 |
Why?
| | Carbon Dioxide | 3 | 2016 | 211 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 815 | 0.190 |
Why?
| | Survival Analysis | 3 | 2013 | 1219 | 0.190 |
Why?
| | Inflammation | 5 | 2014 | 2499 | 0.190 |
Why?
| | Shock, Cardiogenic | 2 | 2020 | 53 | 0.190 |
Why?
| | Cytokines | 3 | 2014 | 1853 | 0.190 |
Why?
| | Propensity Score | 2 | 2019 | 225 | 0.190 |
Why?
| | Mentors | 1 | 2023 | 162 | 0.190 |
Why?
| | KATP Channels | 1 | 2021 | 16 | 0.190 |
Why?
| | Potassium Channels | 1 | 2021 | 121 | 0.190 |
Why?
| | General Surgery | 1 | 2022 | 129 | 0.190 |
Why?
| | Lipopeptides | 1 | 2020 | 14 | 0.190 |
Why?
| | Intraoperative Complications | 2 | 2017 | 126 | 0.190 |
Why?
| | Vascular Grafting | 1 | 2020 | 12 | 0.180 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 154 | 0.180 |
Why?
| | Quality Assurance, Health Care | 2 | 2013 | 315 | 0.180 |
Why?
| | Interprofessional Relations | 1 | 2023 | 258 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2013 | 1405 | 0.180 |
Why?
| | Peroxidase | 3 | 2005 | 157 | 0.180 |
Why?
| | Incidence | 6 | 2020 | 2335 | 0.180 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 279 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2013 | 479 | 0.180 |
Why?
| | Cell Adhesion | 2 | 2018 | 433 | 0.180 |
Why?
| | Cell Proliferation | 4 | 2020 | 2194 | 0.180 |
Why?
| | Cardiomyopathies | 2 | 2019 | 303 | 0.170 |
Why?
| | Surgical Instruments | 1 | 2020 | 48 | 0.170 |
Why?
| | Aortitis | 1 | 2019 | 7 | 0.170 |
Why?
| | Loeys-Dietz Syndrome | 1 | 2019 | 6 | 0.170 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 431 | 0.170 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 125 | 0.170 |
Why?
| | Tricuspid Valve | 1 | 2019 | 23 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 148 | 0.160 |
Why?
| | Patient Selection | 4 | 2019 | 654 | 0.160 |
Why?
| | Swine | 3 | 2006 | 704 | 0.160 |
Why?
| | Creatinine | 1 | 2020 | 430 | 0.160 |
Why?
| | Internship and Residency | 3 | 2020 | 951 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 80 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 273 | 0.150 |
Why?
| | Documentation | 1 | 2020 | 169 | 0.150 |
Why?
| | Filamins | 1 | 2018 | 19 | 0.150 |
Why?
| | Terminology as Topic | 1 | 2019 | 186 | 0.150 |
Why?
| | Drug Synergism | 1 | 2018 | 317 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2021 | 147 | 0.150 |
Why?
| | Electrocardiography | 2 | 2017 | 560 | 0.150 |
Why?
| | ADAMTS5 Protein | 1 | 2017 | 5 | 0.150 |
Why?
| | Hemostatics | 1 | 2018 | 48 | 0.150 |
Why?
| | Phenotype | 8 | 2020 | 2829 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 736 | 0.150 |
Why?
| | Surface-Active Agents | 1 | 2018 | 79 | 0.150 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 86 | 0.140 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 31 | 0.140 |
Why?
| | Blood Pressure | 3 | 2018 | 1537 | 0.140 |
Why?
| | Oxygen Consumption | 3 | 2016 | 573 | 0.140 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 4 | 2019 | 41 | 0.140 |
Why?
| | Graft Survival | 2 | 2023 | 480 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2018 | 262 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1147 | 0.140 |
Why?
| | Vasodilator Agents | 1 | 2018 | 308 | 0.140 |
Why?
| | Lipopolysaccharides | 3 | 2019 | 826 | 0.140 |
Why?
| | Databases, Factual | 3 | 2020 | 1138 | 0.140 |
Why?
| | Biomarkers | 4 | 2022 | 3466 | 0.140 |
Why?
| | Registries | 2 | 2016 | 1770 | 0.140 |
Why?
| | Sinus of Valsalva | 1 | 2016 | 10 | 0.140 |
Why?
| | Nitric Oxide | 1 | 2021 | 832 | 0.140 |
Why?
| | Osteoblasts | 1 | 2017 | 106 | 0.140 |
Why?
| | Administration, Oral | 1 | 2018 | 734 | 0.140 |
Why?
| | Histone Deacetylases | 1 | 2018 | 196 | 0.130 |
Why?
| | Alkaline Phosphatase | 4 | 2019 | 144 | 0.130 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 31 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 449 | 0.130 |
Why?
| | Heart Atria | 1 | 2016 | 110 | 0.130 |
Why?
| | Glucose | 3 | 2023 | 904 | 0.130 |
Why?
| | Mice, Inbred C3H | 2 | 2013 | 244 | 0.130 |
Why?
| | Graft Rejection | 2 | 2023 | 533 | 0.130 |
Why?
| | Patient Safety | 1 | 2019 | 276 | 0.130 |
Why?
| | Heart Ventricles | 3 | 2017 | 712 | 0.130 |
Why?
| | Tissue Donors | 2 | 2023 | 331 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2017 | 251 | 0.130 |
Why?
| | Decompression, Surgical | 2 | 2008 | 93 | 0.130 |
Why?
| | Interleukins | 1 | 2017 | 238 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2018 | 3022 | 0.120 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.120 |
Why?
| | Neutrophil Activation | 2 | 2005 | 94 | 0.120 |
Why?
| | Myocardial Infarction | 2 | 2016 | 931 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 93 | 0.120 |
Why?
| | Asphyxia | 1 | 2014 | 21 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2017 | 222 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 2 | 2006 | 174 | 0.120 |
Why?
| | Kidney Failure, Chronic | 1 | 2019 | 490 | 0.120 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 87 | 0.120 |
Why?
| | Extracellular Matrix Proteins | 1 | 2015 | 127 | 0.120 |
Why?
| | Comorbidity | 3 | 2020 | 1473 | 0.120 |
Why?
| | Aortic Coarctation | 2 | 2006 | 67 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2017 | 298 | 0.120 |
Why?
| | Vascular Patency | 1 | 2014 | 97 | 0.110 |
Why?
| | Limb Salvage | 1 | 2014 | 52 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 203 | 0.110 |
Why?
| | Radiography | 2 | 2006 | 826 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2011 | 155 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2014 | 126 | 0.110 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 73 | 0.110 |
Why?
| | Ligation | 1 | 2013 | 77 | 0.110 |
Why?
| | Oxygen | 4 | 2006 | 837 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 152 | 0.110 |
Why?
| | Pericardium | 2 | 2011 | 50 | 0.110 |
Why?
| | Thrombosis | 2 | 2019 | 302 | 0.110 |
Why?
| | Nerve Degeneration | 1 | 2013 | 40 | 0.110 |
Why?
| | Minocycline | 1 | 2013 | 26 | 0.110 |
Why?
| | Transplantation, Autologous | 1 | 2013 | 173 | 0.110 |
Why?
| | Polyethylene Glycols | 1 | 2018 | 576 | 0.110 |
Why?
| | Sleep Deprivation | 2 | 2005 | 166 | 0.110 |
Why?
| | Vascular Stiffness | 1 | 2017 | 411 | 0.110 |
Why?
| | Mice, Knockout | 3 | 2017 | 2604 | 0.110 |
Why?
| | Consumer Health Information | 1 | 2013 | 47 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 246 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1180 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 165 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1536 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 376 | 0.100 |
Why?
| | Pulmonary Edema | 3 | 2011 | 116 | 0.100 |
Why?
| | Delivery of Health Care | 2 | 2023 | 844 | 0.100 |
Why?
| | Specialties, Surgical | 1 | 2013 | 71 | 0.100 |
Why?
| | Pulmonary Emphysema | 1 | 2015 | 316 | 0.100 |
Why?
| | Foam Cells | 1 | 2011 | 13 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2207 | 0.100 |
Why?
| | Warm Ischemia | 1 | 2011 | 11 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2012 | 127 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6417 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 757 | 0.100 |
Why?
| | Lung Diseases | 2 | 2008 | 710 | 0.090 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 93 | 0.090 |
Why?
| | Physician's Role | 1 | 2013 | 199 | 0.090 |
Why?
| | Coronary Artery Bypass, Off-Pump | 1 | 2010 | 15 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2013 | 370 | 0.090 |
Why?
| | Lipoproteins, LDL | 1 | 2011 | 129 | 0.090 |
Why?
| | Echocardiography, Three-Dimensional | 1 | 2011 | 48 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 607 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 2907 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 331 | 0.090 |
Why?
| | Organ Preservation | 2 | 2023 | 68 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 173 | 0.090 |
Why?
| | Cell Movement | 1 | 2014 | 867 | 0.090 |
Why?
| | Ultrasonography | 1 | 2013 | 641 | 0.090 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2011 | 254 | 0.090 |
Why?
| | Mitral Valve Prolapse | 1 | 2009 | 8 | 0.090 |
Why?
| | Prospective Studies | 4 | 2023 | 6264 | 0.080 |
Why?
| | Bone Morphogenetic Protein 2 | 3 | 2017 | 75 | 0.080 |
Why?
| | Heart Aneurysm | 2 | 2011 | 8 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2012 | 399 | 0.080 |
Why?
| | Equipment Failure | 1 | 2009 | 109 | 0.080 |
Why?
| | Critical Illness | 1 | 2014 | 645 | 0.080 |
Why?
| | Hypoxia | 1 | 2014 | 937 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 4665 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2370 | 0.080 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2014 | 445 | 0.080 |
Why?
| | Collagen | 2 | 2020 | 415 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2015 | 830 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2018 | 2751 | 0.080 |
Why?
| | Work Schedule Tolerance | 2 | 2005 | 36 | 0.080 |
Why?
| | Perfusion Imaging | 2 | 2018 | 44 | 0.080 |
Why?
| | Organ Size | 2 | 2006 | 434 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2011 | 341 | 0.070 |
Why?
| | Blood Preservation | 1 | 2011 | 263 | 0.070 |
Why?
| | Mutation | 1 | 2018 | 3364 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 390 | 0.070 |
Why?
| | Heart Septal Defects | 1 | 2006 | 10 | 0.070 |
Why?
| | Reperfusion | 1 | 2006 | 38 | 0.070 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 659 | 0.070 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2017 | 160 | 0.070 |
Why?
| | Europe | 2 | 2018 | 336 | 0.070 |
Why?
| | Computed Tomography Angiography | 2 | 2018 | 101 | 0.070 |
Why?
| | Blood Flow Velocity | 2 | 2018 | 324 | 0.070 |
Why?
| | Decision Making | 1 | 2013 | 791 | 0.070 |
Why?
| | Triazines | 1 | 2006 | 38 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 963 | 0.070 |
Why?
| | Hemiplegia | 1 | 2006 | 19 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 2 | 2018 | 209 | 0.070 |
Why?
| | Probability | 1 | 2006 | 294 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2020 | 622 | 0.060 |
Why?
| | Methylprednisolone | 1 | 2006 | 83 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2009 | 536 | 0.060 |
Why?
| | Needs Assessment | 1 | 2007 | 318 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 213 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 132 | 0.060 |
Why?
| | Blood Gas Analysis | 1 | 2005 | 69 | 0.060 |
Why?
| | Receptors, Adenosine A2 | 1 | 2004 | 6 | 0.060 |
Why?
| | Actins | 2 | 2017 | 383 | 0.060 |
Why?
| | Severity of Illness Index | 4 | 2005 | 2578 | 0.060 |
Why?
| | Cardiac Output | 1 | 2005 | 143 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1805 | 0.060 |
Why?
| | Random Allocation | 1 | 2005 | 337 | 0.060 |
Why?
| | Recovery of Function | 1 | 2008 | 577 | 0.060 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2004 | 39 | 0.060 |
Why?
| | Models, Animal | 1 | 2006 | 350 | 0.060 |
Why?
| | RNA Interference | 2 | 2017 | 438 | 0.060 |
Why?
| | Paraparesis | 1 | 2023 | 6 | 0.060 |
Why?
| | Transfection | 2 | 2017 | 866 | 0.060 |
Why?
| | Thoracic Outlet Syndrome | 1 | 2003 | 12 | 0.060 |
Why?
| | Respiratory Function Tests | 1 | 2005 | 535 | 0.060 |
Why?
| | Brain Death | 1 | 2023 | 32 | 0.050 |
Why?
| | Morbidity | 2 | 2020 | 278 | 0.050 |
Why?
| | Vasodilation | 1 | 2006 | 412 | 0.050 |
Why?
| | Travel | 1 | 2023 | 121 | 0.050 |
Why?
| | Virginia | 3 | 2010 | 51 | 0.050 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2003 | 114 | 0.050 |
Why?
| | Antithrombins | 1 | 2022 | 49 | 0.050 |
Why?
| | Cyanoacrylates | 1 | 2001 | 4 | 0.050 |
Why?
| | Ulcer | 1 | 2021 | 28 | 0.050 |
Why?
| | Glutaral | 1 | 2001 | 15 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2003 | 225 | 0.050 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2001 | 13 | 0.050 |
Why?
| | Hematoma | 1 | 2021 | 50 | 0.050 |
Why?
| | Death | 1 | 2022 | 109 | 0.050 |
Why?
| | Contraindications | 1 | 2001 | 86 | 0.050 |
Why?
| | Antioxidants | 1 | 2005 | 533 | 0.050 |
Why?
| | Drainage | 1 | 2022 | 151 | 0.050 |
Why?
| | Young Adult | 4 | 2018 | 10470 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1893 | 0.050 |
Why?
| | Seizures | 1 | 2023 | 344 | 0.050 |
Why?
| | A549 Cells | 1 | 2020 | 51 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1642 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 850 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 187 | 0.040 |
Why?
| | Warfarin | 1 | 2021 | 136 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 333 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 845 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2019 | 45 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1718 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 177 | 0.040 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 467 | 0.040 |
Why?
| | beta Catenin | 1 | 2021 | 220 | 0.040 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2019 | 90 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 292 | 0.040 |
Why?
| | Thrombectomy | 1 | 2019 | 53 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 156 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 341 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2018 | 366 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1870 | 0.040 |
Why?
| | Sex Distribution | 1 | 2019 | 337 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 220 | 0.040 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 78 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2022 | 458 | 0.040 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 99 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2262 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 465 | 0.040 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2018 | 5 | 0.040 |
Why?
| | Connectin | 1 | 2018 | 30 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2022 | 1660 | 0.040 |
Why?
| | Clinical Competence | 2 | 2020 | 912 | 0.040 |
Why?
| | Hemostasis, Surgical | 1 | 2018 | 21 | 0.040 |
Why?
| | Washington | 1 | 2018 | 134 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 80 | 0.040 |
Why?
| | Risk | 1 | 2020 | 819 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 149 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2011 | 1083 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 126 | 0.040 |
Why?
| | Advisory Committees | 1 | 2019 | 208 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 292 | 0.040 |
Why?
| | Matrilin Proteins | 1 | 2017 | 7 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2017 | 37 | 0.040 |
Why?
| | Sp7 Transcription Factor | 1 | 2017 | 7 | 0.040 |
Why?
| | Antagomirs | 1 | 2017 | 13 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 941 | 0.040 |
Why?
| | Cross-Linking Reagents | 1 | 2018 | 182 | 0.040 |
Why?
| | Potassium | 1 | 1997 | 128 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2017 | 76 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 372 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2018 | 402 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1440 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 199 | 0.030 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1031 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 302 | 0.030 |
Why?
| | Marfan Syndrome | 1 | 2016 | 41 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2016 | 34 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 770 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2017 | 440 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 220 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 443 | 0.030 |
Why?
| | Rats | 2 | 2018 | 5034 | 0.030 |
Why?
| | Tensins | 1 | 2014 | 2 | 0.030 |
Why?
| | Aminosalicylic Acids | 1 | 2014 | 6 | 0.030 |
Why?
| | Benzenesulfonates | 1 | 2014 | 21 | 0.030 |
Why?
| | Hydrogels | 1 | 2001 | 581 | 0.030 |
Why?
| | Vascular Resistance | 2 | 2011 | 338 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 281 | 0.030 |
Why?
| | Administration, Inhalation | 2 | 2006 | 644 | 0.030 |
Why?
| | Thrombelastography | 1 | 2015 | 179 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 307 | 0.030 |
Why?
| | Adolescent | 3 | 2023 | 17889 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2006 | 1044 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2014 | 161 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 168 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2082 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2018 | 457 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2013 | 50 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 1598 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 445 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1971 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 526 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 930 | 0.030 |
Why?
| | Osteopontin | 1 | 2012 | 32 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 601 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2574 | 0.030 |
Why?
| | Hypertension | 1 | 2020 | 1064 | 0.030 |
Why?
| | Smoking | 1 | 2019 | 1457 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 2264 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 2012 | 78 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2019 | 783 | 0.020 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 1970 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 906 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 177 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2011 | 60 | 0.020 |
Why?
| | Emergency Treatment | 1 | 2012 | 113 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2800 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 184 | 0.020 |
Why?
| | Peptidoglycan | 1 | 2011 | 25 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 271 | 0.020 |
Why?
| | Culture Media | 1 | 2011 | 156 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2353 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 185 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 1918 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 105 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 499 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 526 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 959 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 501 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 128 | 0.020 |
Why?
| | Odds Ratio | 1 | 2010 | 962 | 0.020 |
Why?
| | Biopsy | 1 | 2011 | 1056 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 517 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 28 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 526 | 0.020 |
Why?
| | Gases | 1 | 2006 | 38 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2006 | 178 | 0.020 |
Why?
| | Pressure | 1 | 2006 | 220 | 0.020 |
Why?
| | Logistic Models | 1 | 2010 | 1856 | 0.020 |
Why?
| | Motor Skills | 1 | 2006 | 80 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1265 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 374 | 0.020 |
Why?
| | Arteries | 1 | 2006 | 250 | 0.020 |
Why?
| | Hyperoxia | 1 | 2005 | 97 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 1700 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1490 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2006 | 608 | 0.010 |
Why?
| | Heart Function Tests | 1 | 2003 | 59 | 0.010 |
Why?
| | Fatigue | 1 | 2005 | 296 | 0.010 |
Why?
| | Clavicle | 1 | 2003 | 31 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2004 | 299 | 0.010 |
Why?
| | Child, Preschool | 2 | 2006 | 9133 | 0.010 |
Why?
| | Infant | 2 | 2006 | 7979 | 0.010 |
Why?
| | Stroke Volume | 1 | 2004 | 509 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 920 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2003 | 585 | 0.010 |
Why?
| | Hypertonic Solutions | 1 | 1997 | 8 | 0.010 |
Why?
| | Atrial Function, Left | 1 | 1997 | 5 | 0.010 |
Why?
| | Buffers | 1 | 1997 | 54 | 0.010 |
Why?
| | Lung Compliance | 1 | 1997 | 49 | 0.010 |
Why?
| | Tidal Volume | 1 | 1997 | 74 | 0.010 |
Why?
| | Dextrans | 1 | 1997 | 74 | 0.010 |
Why?
| | Blood | 1 | 1997 | 97 | 0.010 |
Why?
| | Cryopreservation | 1 | 1997 | 93 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1749 | 0.010 |
Why?
| | Child | 1 | 2006 | 18488 | 0.000 |
Why?
|
|
Reece's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|